Engineers Gate Manager LP Has $372,000 Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Engineers Gate Manager LP cut its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Rating) by 78.6% during the third quarter, Holdings Channel.com reports. The fund owned 540 shares of the biopharmaceutical company’s stock after selling 1,986 shares during the period. Engineers Gate Manager LP’s holdings in Regeneron Pharmaceuticals were worth $372,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in REGN. Markel Corp boosted its holdings in Regeneron Pharmaceuticals by 1.3% during the first quarter. Markel Corp now owns 80,300 shares of the biopharmaceutical company’s stock worth $56,083,000 after buying an additional 1,000 shares during the last quarter. Cibc World Market Inc. raised its holdings in Regeneron Pharmaceuticals by 1.4% in the first quarter. Cibc World Market Inc. now owns 6,416 shares of the biopharmaceutical company’s stock worth $4,481,000 after purchasing an additional 86 shares during the period. Blair William & Co. IL boosted its position in shares of Regeneron Pharmaceuticals by 18.4% during the first quarter. Blair William & Co. IL now owns 1,431 shares of the biopharmaceutical company’s stock worth $999,000 after purchasing an additional 222 shares in the last quarter. Sequoia Financial Advisors LLC raised its stake in Regeneron Pharmaceuticals by 23.1% during the 1st quarter. Sequoia Financial Advisors LLC now owns 495 shares of the biopharmaceutical company’s stock worth $346,000 after buying an additional 93 shares during the period. Finally, Baird Financial Group Inc. lifted its holdings in Regeneron Pharmaceuticals by 100.9% during the first quarter. Baird Financial Group Inc. now owns 36,529 shares of the biopharmaceutical company’s stock worth $25,513,000 after acquiring an additional 18,345 shares in the last quarter. Institutional investors own 84.25% of the company’s stock.

Regeneron Pharmaceuticals Trading Up 0.7 %

Shares of Regeneron Pharmaceuticals stock opened at $752.33 on Tuesday. The company has a quick ratio of 4.29, a current ratio of 5.06 and a debt-to-equity ratio of 0.12. Regeneron Pharmaceuticals, Inc. has a 12-month low of $538.01 and a 12-month high of $800.48. The company has a market capitalization of $82.25 billion, a price-to-earnings ratio of 19.67, a PEG ratio of 2.57 and a beta of 0.21. The firm’s 50-day moving average price is $744.30 and its two-hundred day moving average price is $725.99.

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Rating) last posted its quarterly earnings results on Friday, February 3rd. The biopharmaceutical company reported $12.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $8.18 by $4.38. Regeneron Pharmaceuticals had a net margin of 35.64% and a return on equity of 22.87%. The business had revenue of $3.41 billion for the quarter, compared to analyst estimates of $3.11 billion. During the same quarter last year, the business posted $23.72 EPS. The firm’s revenue for the quarter was down 31.1% on a year-over-year basis. On average, analysts forecast that Regeneron Pharmaceuticals, Inc. will post 34.22 earnings per share for the current fiscal year.

Insider Activity

In other news, Director N Anthony Coles sold 5,758 shares of the business’s stock in a transaction on Wednesday, December 28th. The stock was sold at an average price of $714.11, for a total transaction of $4,111,845.38. Following the completion of the transaction, the director now owns 1,093 shares of the company’s stock, valued at approximately $780,522.23. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In related news, Director N Anthony Coles sold 5,758 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Wednesday, December 28th. The shares were sold at an average price of $714.11, for a total transaction of $4,111,845.38. Following the sale, the director now directly owns 1,093 shares of the company’s stock, valued at approximately $780,522.23. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Arthur F. Ryan sold 100 shares of the company’s stock in a transaction that occurred on Wednesday, March 1st. The stock was sold at an average price of $762.50, for a total transaction of $76,250.00. Following the transaction, the director now owns 19,147 shares of the company’s stock, valued at $14,599,587.50. The disclosure for this sale can be found here. In the last quarter, insiders have sold 27,273 shares of company stock worth $21,189,979. Insiders own 8.99% of the company’s stock.

Analysts Set New Price Targets

A number of research firms recently issued reports on REGN. Royal Bank of Canada increased their target price on Regeneron Pharmaceuticals from $787.00 to $806.00 and gave the stock a “sector perform” rating in a research note on Thursday, March 9th. StockNews.com raised Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, February 23rd. Morgan Stanley upped their price target on Regeneron Pharmaceuticals from $868.00 to $873.00 and gave the stock an “overweight” rating in a research report on Tuesday, January 24th. SVB Leerink boosted their price objective on shares of Regeneron Pharmaceuticals from $770.00 to $834.00 and gave the stock a “market perform” rating in a research report on Monday, February 6th. Finally, Cowen upgraded shares of Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating and boosted their price objective for the stock from $775.00 to $875.00 in a research note on Monday, January 30th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and fifteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $804.10.

Regeneron Pharmaceuticals Company Profile

(Get Rating)

Regeneron Pharmaceuticals, Inc is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies.